The market opened sharply lower this morning anticipating, perhaps, unemployment data that was worse than the data turned out to be. The September unemployment rate rose to 9.8%, exactly what most observers had been expecting.

The markets tried to gain back more than all the early losses, with all three major indexes ending slightly down. Crude oil has fallen below $70/barrel again, and gold has broken through $1,000/oz again. It could just be the case that the nearly 60% run-up since March in the S&P 500 was just wishful thinking that the economy was turning around and that consumer spending would would tick up as things improved. That thinking has not been borne out yet, so markets are likely to wobble around until the consumer decides what to do -- save or spend. The holiday season could write the ending to the story.

Here are todays unofficial closing numbers:

Dow 9,487.37 -21.91 (-0.23%)
S&P 500 1,025.18 -4.67 (-0.45%)
Nasdaq 2,048.11 -9.37 (-0.46%)

Late Thursday, Standard & Poor's announced a few changes to its U.S. indices. The reason for the changes are that Wyeth (NYSE: WYE) is being acquired by Pfizer (NYSE: PFE), leaving an opening in both the S&P 100 and S&P 500 (SPX). I want to focus on the stock that will replace WYE in the SPX, First Solar (NASDAQ: FSLR). In after-hours trading, FSLR jumped more than 6% in response to the announcement.

FSLR manufactures solar modules and is a major benefactor of what I like to call the "green rush" that took place during the past two years. FSLR capitalized nicely on the global environmental consciousness revolution last year, ascending as high as the $310 region. Yes, the stock has backed off quite a bit due to the economic crisis, but it could enjoy a bit of a recovery provided it can parlay this latest news into a breach of some overhead resistance.

All three of the major indexes finished Tuesday in the red, but there were several big names that moved up to new 52-week highs in Tuesday's trading.

Walgreen Co. (NYSE: WAG): The drugstore giant had a really good day on Wall Street after posting better than expected earnings in the morning before the market opened. The company posted earnings of 44 cents per share versus analyst estimates of 39 cents. The stock set a new 52-week high of $38.44 and closed the day up 9.2% at $37.35.

The mega pharmaceutical merger between Wyeth (NYSE: WYE) and Pfizer (NYSE: PFE) is one step closer to becoming official today after overwhelming approval by Wyeth shareholders.

The shareholder vote to sell Wyeth to Pfizer was not even close. Around 98% of shareholders voted to approve the sale, which is expected to happen by the end of the year.

Mergers and acquisitions aren't delivering the fees that investment bankers used to enjoy, but fortunately, the money's coming from elsewhere. Data from Thomson Reuters reports a 29% increase in capital markets and M&A fees for the first time in more than a year. Share sales (e.g., rights offerings) were where dealmakers found the action. In the shrinking M&A space, Morgan Stanley (NYSE: MS) has taken the lead spot.

Since there are fewer banks in the marketplace than there were a year ago -- and they have less money -- the capital is starting to come from elsewhere. Because they aren't lending at their previous pace, companies are issuing bonds and equity to replenish their coffers. Pfizer (NYSE: PFE), for example, raked in more than $23 billion from the bond market to fund its acquisition of Wyeth (NYSE: WYE), and Roche nabbed Genentech with the help of a $30 billion debt issuance.

If you've been following Elan Corp. (NYSE: ELN) lately, you've probably come to take any story of a deal, takeover, sale with a grain of salt.

This morning, Elan shares soared over 16% after stories on Reuters and the Wall Street Journal over the weekend said it is in advanced talks to sell a minority stake to Bristol-Myers Squibb (NYSE: BMY). Moreover, Elan was said to be in talks with a second suitor, but the status of those discussions was unclear. This, Reuters reported, could be the first move in a multi-step transaction to sell Elan outright.

While the shares are still up a healthy 12% by midday, now Bloomberg reports that according to UBS analysts, Bristol isn't in talks to buy a stake in Elan.

Pfizer (NYSE: PFE), a pharmaceutical entity whose colleagues include Merck (NYSE: MRK), Novartis (NYSE: NVS), and Johnson & Johnson (NYSE: JNJ), will be reporting first-quarter earnings Tuesday. As one has come to expect, the market believes that the company will be experiencing a decline in bottom-line income. The call is for 49 cents per share versus 61 cents per share in the year-ago period.

That's a drop of 20%. That might not sound so hot, but the good news is that Pfizer has a solid recent track record when it comes to beating earnings expectations. So shareholders might be justified in feeling confident about that aspect of the game.

Wyeth (NYSE: WYE) closed at $43.11. Pfizer (NYSE: PFE) announced on January 26 the acquisition of WYE for $33 in cash and 0.985 of a share of PFE. PFE closed at $14.04. WYE April and May option implied volatility of 23 is near its 13-week average of 23, according to Track Data, suggesting non-directional price movement.

Schering-Plough (NYSE: SGP) and Merck (NYSE: MRK) approved a definite merger agreement on March 9. SGP shareholders will receive 0.5767 shares and $10.50 in cash for each share of SGP. SGP closed at $24.19. MRK closed at $27.16. SGP April and May option implied volatility of 37 is near its 2-week average according to Track Data, suggesting non-directorial price movement.

Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

"Long-time healthcare investors can be forgiven their confusion; drug stocks are supposed to be defensive, but many of the largest drugmakers have been pounded," observes Richard Moroney.

Nevertheless, in the blue chip Dow Theory Forecasts, the advisor sees two favorite healthcare and pharmaceutical issues as long-term opportunities: AstraZeneca (NYSE: AZN) and Johnson & Johnson (NYSE: JNJ).

Moroney explains, "Healthcare companies' profits are supposed to remain fairly steady regardless of the economic situation. But hospitals' capital spending fell in the December quarter, and many consumers are putting off medical care because they cannot afford it.

The shares of Dow component Pfizer Inc. (NYSE: PFE) slipped to a fresh 52-week low out of the gate this morning, after the pharmaceutical firm said it was canceling development of two experimental drugs in late-stage trials. Pfizer is scrapping work on esreboxetine, a fibromyalgia treatment, and PD 332,334, a drug for generalized anxiety disorder, because "it was considered unlikely that either compound would provide meaningful benefit to patients beyond the current standard of care."

Currently, Pfizer is fumbling to find a replacement for its successful cholesterol drug, Lipitor, which loses patent protection in 2011. The pharma firm isn't having much luck, though. Two late-stage drugs for pancreatic cancer and for obesity were also recently dust-binned after disappointing study results.

Analyst upgrades:

• Jefferies upgraded NeuStar (NYSE:NSR) to Hold from Underperform on valuation following the recent weakness and raised their target price to $15 from $12.
  
• Oppenheimer upgraded Adobe Systems (NASDAQ:ADBE) to Outperform from Perform on valuation as they believe the recent pullback has created an attractive entry point into the name. The firm has a $27 target on the stock.
  
• UBS upgraded Pfizer (NYSE:PFE) and Wyeth (NYSE:WYE) to Buy from Neutral based on valuations. Pfizer's price target remains $18 and Wyeth's was raised to $50 from $38.
• Methanex (NASDAQ:MEOH) was upgraded to Sector Outperformer from Sector Performer at CIBC.
  
• BHP Billiton (NYSE:BHP) was raised to Buy from Hold at RBS.
  
• Anadys Pharma (NASDAQ:ANDS) was upgraded to Buy from Neutral at Piper Jaffray.

Here are some highlights from this past week's earnings coverage from BloggingStocks:

• Amazon.com Inc. (NASDAQ: AMZN) shares surged after earnings easily topped Q4 expectations.
• AT&T Inc. (NYSE: T) reported that its Q4 earnings fell while its revenue rose marginally.
• Boeing Co. (NYSE: BA) posted a big loss and lower revenue due to strikes and design changes.
• Caterpillar Inc. (NYSE: CAT) reported that Q4 profit fell despite higher revenue and lowered its guidance.
• Danaher Corp. (NYSE: DHR) lower Q4 profit topped analysts' estimates, sending shares higher.
• Eastman Kodak Co. (NYSE: EK) reported a Q4 net loss and announced additional job cuts.

Amazon.com (NASDAQ: AMZN) reported fourth-quarter earnings that topped Wall Street's expectations late Thursday. The online retailer's fourth-quarter profit rose 9% to $225 million, or 52 cents per share, trouncing expectations of 39 cents per share. Revenue rose 18% to $6.7 billion, again exceeding analyst estimates for $6.4 billion. Even for the current quarter Amazon gave guidance that was better than expectations. AMZN shares are soaring about 15% in premarket trading.

Procter & Gamble (NYSE: PG), a Dow component, reported earnings this morning, meeting analyst expectations of a $1.58 per share profit for the quarter. P&G's quarterly profit jumped 53% due to a gain from the sale of its Folgers coffee business. One problem, though, sales unexpectedly declined 3% to $20.37 billion. PG shares traded 2.8% lower in premarket action.

Here's a quick look at some of Monday's earnings results:

Netflix Inc.'s (NASDAQ: NFLX) fourth-quarter earnings jumped 45% percent to nearly $23 million, or 38 cents per share, which surpassed analysts' estimates. Revenue in the period rose 19% to $360 million. The company ended 2008 with 9.4 million subscribers, a gain of 718,000 customers from the end of September. Shares fell $0.29, less than 1% Monday.

Amgen Inc.'s (NASDAQ: AMGN) fourth-quarter profit grew 15% percent to $961 million, or 91 cents per share, mostly due to lower expenses. Revenue was $3.75 billion about the same as last year. Results included $60 million in restructuring costs a year ago. Shares rose $1.22, or 2.3%, but fell in after-hours trading.

Pfizer Inc. (NYSE: PFE) announced a deal to acquire rival Wyeth (NYSE: WYE) for $68 billion, or $50.19 a share, a 15% premium to Friday's close of $43.74. This cash-and-stock deal is the largest in the drug sector since 2000 and many see it as a precursor to a flourishing M&A season as the credit markets are slowly starting to improve. Pfizer also reported a 90% profit drop for the fourth quarter due to charges. PFE shares declined 3.4% in premarket trading, while WYE shares gained nearly 5%.

Barclays (NYSE: BCS) shares surged in London Monday after the firm reassured investors in a letter to shareholders it didn't need more capital. But France's BNP Paribas said it would take more cash from the government following a 1.4 billion euro ($1.8 billion) loss in the latest quarter. Finally, ING (NYSE: ING), the Dutch financial services firm, also received government aid as it is expected to announce it had a net loss of 3.3 billion euros in the fourth quarter, that it would cut 7,000 jobs, and that its CEO would step down. BCS shares gained over 44% in premarket trading and ING's gained over 19%.

Caterpillar (NYSE: CAT) and McDonald's (NYSE: MCD) are two Dow components set to report earnings this morning. CAT said its fourth-quarter profit fell to $661 million, or $1.08 a share, from $975 million, or $1.50 a share, in the year-ago quarter. Revenue rose 6% to $12.9 billion. For 2009, Caterpillar gave a a much lower guidance than analysts had expected, $2.50 vs. $4.35 EPS. CAT also said it would slash 20,000 jobs. CAT shares fell over 11% in premarket trading.
Meanwhile, MCD delivered what at first glance seems to be better-than-expected earnings of 87 cents vs. 84 cents. It even plans to invest $2.1 billion of capital to open about 1,000 new McDonald's restaurants.

American Express (NYSE: AXP) is the third Dow component tor report quarterly results after the close of trading today and is expected to report fourth-quarter earnings of 20 cents a share.